Axsome Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Axsome Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Feb 28, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $638.50M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $385.69M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $270.60M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $50.04M | Feb 18, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($183.17M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($287.22M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($239.24M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($187.13M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($130.40M) | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | ($29.16M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($22.92M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($18.33M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($32.48M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($24.81M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($166.76M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($280.56M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($231.83M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($179.80M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($124.71M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($99.14M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($67.25M) | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | $9.45M | Mar 15, 2019 |
| FY2018 | Sep 30, 2018 | $8.24M | Mar 15, 2019 |
| FY2018 | Jun 30, 2018 | $7.99M | Mar 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.28M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $187.08M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $97.94M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $57.95M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $58.06M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $70.24M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $53.65M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $23.50M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $19.96M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $21.20M | Mar 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $570.60M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $411.36M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $323.12M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $159.25M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $66.65M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $28.90M | Feb 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.41M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($128.41M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($145.08M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($116.51M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($108.23M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | ($78.46M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($46.38M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($30.05M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($26.47M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($21.28M) | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.0K | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $270.0K | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $582.0K | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $702.0K | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $308.0K | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $45.9K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $16.1K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $32.7K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $9.9K | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $104.6K | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $689.81M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $568.50M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $588.24M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $331.48M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $87.79M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $186.13M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $220.55M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $15.38M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $35.56M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $38.21M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $601.51M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $511.48M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $397.26M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $221.92M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $72.15M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $72.34M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $41.83M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $14.44M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $18.84M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $16.64M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.30M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $57.02M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $190.98M | Feb 23, 2026 |
| FY2025 | Dec 31, 2022 | $109.56M | Feb 23, 2026 |
| FY2024 | Dec 31, 2021 | $15.63M | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $113.79M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $178.72M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $937.9K | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $16.72M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $21.57M | Mar 12, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.04M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $12.04M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $12.04M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $10.31M | Feb 23, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.31B) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($1.12B) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($835.57M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($596.33M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | ($409.20M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($278.80M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($175.90M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($107.55M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($76.58M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($47.64M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.93M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $315.35M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $386.19M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $200.84M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $86.47M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $183.88M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $219.97M | Mar 1, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.88M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 48.67M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 47.35M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 43.50M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 37.82M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 37.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 36.93M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 30.09M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 25.49M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 19.15M | Mar 7, 2018 |